ТЕРАПЕВТИЧЕСКИЙ ПОТЕНЦИАЛ СОВРЕМЕННЫХ ПРОБИОТИКОВ
https://doi.org/10.15690/pf.v10i2.644
Аннотация
В дискуссионной статье приведен краткий обзор клинических исследований, при которых применение пробиотиков продемонстрировало лучшие результаты. Обсуждаются вопросы о способности пробиотиков оказывать протективное действие на кишечный барьер, антагонистическое ― на условно-патогенные микроорганизмы и стимулирующее ― на иммунитет. Рассматриваются наиболее изученные производственные виды и штаммы, входящие в состав пробиотических препаратов. Представлены различия между моноштаммовыми и мультивидовыми пробиотиками. Обосновывается целесообразность применения комбинированных препаратов с сочетанными аддитивными или синергическими штаммоспецифическими эффектами.
Об авторе
Н. И. Урсова
Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского, Российская Федерация
Россия
доктор медицинских наук, профессор, главный научный сотрудник педиатрического отделения МОНИКИ
Россия
доктор медицинских наук, профессор, главный научный сотрудник педиатрического отделения МОНИКИ
Список литературы
1. Шендеров Б. А. Медицинская микробная экология и функциональное питание. Пробиотики и функциональное питание. М.: Грантъ. 2001; 3: 286.
2. Szajewska H., Mrukowicz J. Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo controlled trials. J Pediatr Gastroenterol Nutr. 2001; 33: 17–25.
3. Bezkorovainy A. Probiotics: determinants of survival and growth in the gut. Am J Clin Nutr. 2001; 73: 399–405.
4. Бондаренко В. М. Фарматека. 2012; 13: 89–99.
5. Gorbach S. L. Probiotics and gastrointestinal health. Am G Gastroenterol. 2000; 95 (Suppl. 1): 2–4.
6. Hunter J. O., Madden J. A. А review of the role of the gut microflora in irritable bowel syndrome and the effect of probiotics. Br J Nutr. 2002; 88 (Suppl. 1): 67–72.
7. Marteau P. R., de Vrese M., Cellier C. J., Schrezenmeir J. Protection from gastrointestinal diseases with use of probiotics. Am J Clin Nutr. 2001; 73 (Suppl. 2): 430–36.
8. Rolfe R. D. The role of probiotic cultures in the control of gastrointestinal health. J Nutr. 2000; 130 (Suppl. 2S): 396–402.
9. Mercenier A., Pavan S., Pot B. Probiotics as biotherapeutic agent: present khuwledge and future prospects. Curr Pharm Des. 2003; 9: 175–91.
10. Guidelines for the evaluation of probiotics in food: Joint FAO/WHO Working Group meeting. London, Ontario, Canada, 30 April — 1 May. 2002.
11. Shida K., Nanno M. Probiotics and immunology: separating the wheat from the chaff. Trends Immynol. 2008; 29: 565–73.
12. Chapman T. M., Plosker G. L., Figgitt D. P. VSL#3 probiotic mixture: a review of its use in chronic inflammatory bowel diseases. Drugs. 2006; 66 (10): 1371–87.
13. Rachmilevitz D., Katakura K., Karmeli F. et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effect of probiotics murine experimental colitis. Gastroenterol. 2004; 126 (2): 520–28.
14. Bergonzelli G. E., Blum S., Brussow H. et al. Probiotics as a treatment strategy for gastrountestinal diseases? Digestion. 2005; 72: 57–68.
15. Penner R., Fedorak R. N., Madsen K. L. Probiotics and nutraceuticals: non-medicinal treatments of gastrointestinal diseases. Curr Opin Pharmacol. 2005; 5: 596–603.
16. Ghadimi D., Folster-Holst R. Effects of probiotic bacteria and their genomic DNA on TH1/TH2-cytokine production by peripheral blood mononuclear cells (PBMCs) of healthy and allergic subjects. Immunobiology. 2008; 213: 677–92.
17. Metchnikoff E. The prolongation of life. Optimistic studies. London, United Kingdom: William Heinemann. 1907.
18. Reid G. Regulatory and clinical aspects of dairy probiotics. FAO/WHO Expert consultation on evalution of health and nutritional properties of powder milk with live lactic acid bacteria. Cordoba, Argentina. 2001. Р. 1–34.
19. FAO/WHO. The food and agriculture organization of the United Nations and the World Health Organization Joint FAO/WHO expert consultation on evalution of health and nutritional propecties of probiotics in food including powder milk with live lactic acid bacteria. 2001 (10–1).
20. Timmerman H. M., Koning C. J. M., Mulder L., Rombouts F. M., Beynen A. C. Monostrain, multistrain and multispecies probiotics. A comparison of functionality and efficacy. Int J Food Microbiol. 2004; 96: 219–33.
21. Salminen S., Isolauri E., Onela T. Gut flora in normal and disordered states. Chemotherapy. 1995; 41 (Suppl. 1): 5–15.
22. Van der Waaij D. Colonization resistance of the Digestive Tract. Japan. 1999. Р. 76–81.
23. Постникова Е. А., Пикина А. П., Кафарская Л. И., Ефимов Б. А. Журн. микробиол. 2004; 1: 67–69.
24. Fons M., Gomez A., Karjalainen T. Mechanisms of colonization and colonization resistance of the digestive tract. Microbial Ecol Health Dis Sup. 2000; 2: 240–6.
25. Bry L., Falk P. G., Midtvedt T., Gordon J. I. A model of hostmicrobial interactions in an open mammalian ecosystem. Science. 1996; 273 (5280): 1380–3.
26. Hooper L. V., Xu J., Falk P. G., Midtvedt T., Gordon J. I. A molecular sensor that allows a gut commensal to control its nutrient foundation in a competitive ecosystem. Proc Natl Acad Sci. USA. 1999; 96 (17): 9833–8.
27. Mowat A. M. Anatomical basis of tolerance and immunity to intestinal antigens. Nat Rev Immunol. 2003; 3 (4): 331–41.
28. Kelly D., Conway S., Aminov R. Commensal gut bacteria: mechanisms of immune modulation. Trends Immunol. 2005; 26 (6): 326–33.
29. Mayer L., Shao L. Therapeutic potential of oral tolerance. Nat Rev Immunol. 2004; 4 (6): 407–19.
30. Hawrylowicz C. M., O'Garra A. Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma. Nat Rev Immunol. 2005; 5 (4): 271–83.
31. Kapsenberg M. L. Dendritic-cell control of pathogen-driven T-cell polarization. Nat Rev Immunol. 2003; 3 (12): 984–93.
32. Holzapfel W. H., Haberer P., Geisen R. et al. Taxonomy and important features of probiotic microorganisms in food and nutrition. Am J Clin Nutr. 2001; 73: 365–73.
33. Lee Y. K., Lim C. Y., Teng W. L. et al. Quantitative approach in the study of adhesion of lactic acid bacteria to intestinal cells ant their competition with enterobacteria. Appl Envir Microbiol. 2000; 66 (9): 3692–97.
34. O'Sullivan D. J. Screening of intestinal microflora for effective probiotic bacteria. J Ag Food Chem. 2001; 49: 1751–60.
35. Schell M. A., Karmirantzou M., Snel B. et al. The genome sequence of Bifidobacterium longum reflect its adaptation to the human gastrointestinal tract. Proc Natl Sci. USA. 2002; 99 (22): 14422–27.
36. Tannock G. W. Molecular assessment of intestinal microflora. Am J Clin Nutr. 2001; 73: 410–14.
37. Resta-Lenert S., Barrett K. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli. Gut. 2003; 52: 988–997.
38. Putaala H., Salusjarvi T. Effect of four probiotic strains and Echerichia coli O157: H7 on tight junction integrity and cyclooxygenase expression. Res Microbiol. 2008. Doi:10.1016/ j.resmic.2008.08.002.
39. Gill H. S. Probiotic to enhance anti-infective defenses in the gastrointestinal tract. Best Pract Res Clin Gastroenterol. 2003; 17: 755–73.
40. Oksaharju A., Kankainen M., Kekkonen R. A. et al. Probiotic Lactobacillus rhamnosus downregulates FCER1 and HRH4 expression in human mast cell. World J Gastroenterol. 2011; 17: 750–9.
41. Alakomi H. L., Skytta E., Saarela M. et al. Lactic acid permebilizes gram-negative bacteria by disrupting the outer membrane. Applied Environ Microbiol. 2000; 66: 2001–5.
42. Pan X., Chen F., Wu T. et al. The acid, bile tolerance and antimicrobial property of Lactobacillus acidophilus NIT. Food Control. 2008. Doi:10.1016/j.foodcont.2008.08.019.
43. Salminen S., Salminen E. Lactulose lactic acid bacteria intestinal microecology and mucosal protection. Scand J Gastroenterol. 1997; 222: 45–8.
44. Lanning D. K., Rhee K. J., Knight K. L. Intestinal bacteria and development of the B-lymphocyte repertoire. Trends Immunol. 2005; 26 (8): 419–25.
45. Cotter P. D., Hill C., Ross R. P. Developing innate immunity for food. Nat Rev Microbiol. 2005; 3: 777–88.
46. Strompfova V., Laukova A. In vitro study on bacteriocin production of Enterococci associated with chickens. Anaerobe. 2007; 13: 228–37.
47. Chavez A. M., Menconi M. J., Hodin R. A. et al. Cytokineinduced intestinal epithelial hyperpermeability: role of nitric oxide. Crit Care Med. 1999; 27: 2246–51.
48. Sobko T., Reinders C. L., Jansson E. A. et al. Gastrointestinal bacteria generate nitric oxide from nitrate and nitrite. Nitric Oxide. 2005; 13: 163–69.
49. Lundberg J. O., Weitzberg E., Cole J. A. et al. Nitrate, bacteria and human health. Nat Rev Microbiol. 2004; 2: 593–602.
50. Lu L., Walker A. Pathologic and physiologic interactions of bacteria with the gastrointestinal epithelium. Am J Clin Nutr. 2001; 73: 1124–30.
51. Lebeer S., Vanderleydes G., De Keersmaecker S. C. Genes and molecules of lactobacillus supporting probiotic action. Microbiol Mol Biol Rev. 2008; 72: 728–64.
52. Perdigon G., Fuller R., Raya R. Lactis acid bacteria and their effect on the immune system. Curr Issues Intest Microbiol. 2001; 2 (1): 27–42.
53. Лиходед В. Г., Бондаренко В. М. Антиэндотоксиновый иммунитет в регуляции численности микрофлоры кишечника. М.: Медицина. 2007. 216 с.
54. Vinderola G., Matar C., Perdigon G. Role of intestinal epithelial cells in immune effects mediated by gram-positive probiotic bacteria: involvement of toll-like receptors. Clin Diagn Lab Immunol. 2005; 12 (9): 1075–84.
55. Isolauri E., Juntunen M., Rautanen T. et al. A human Lactobacillus strain (Lactobacillus casei sp strain GG) promotes recovery from acute diarrhea in children. Pediatrics. 1991; 88: 90–7.
56. Isolauri E., Salminen S., Ouwehand A. C. Microbial-gut interactions in health and disease. Probiotics. Best Pract Res Clin Gastroenterol. 2004; 18: 299–313.
57. Isolauri E., Kirjavainen P. V., Salminen S. Probiotics: role in the treatment of intestinal infection and inflammation. Gut. 2002; 50 (3): 154–59.
58. Walker W. A., Goulet O., Morelli L. et al. Progress in the science of probiotics: from cellular microbiology and applied immunology to clinical nutrition. Eur J Nutr. 2006; 45: 1–18.
59. Бондаренко В. М. Фарматека. 2010; 2: 26–32.
60. Allen S. J., Okoko B., Martinez E., Gregorio G., Dans L. F. Probiotics for treating infectious diarrhea. Cochrane Database Syst Rev. 2004; 2: CD003048.
61. Lee M. C., Lin L. H., Hung K. L., Wu H. Y. Oral bacterial therapy promotes recovery from acute diarrhea in children. Acta Paediatr. Taiwan. 2001; 42: 301–5.
62. Sazawal S., Hiremath G., Dhingra U. et al. Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised, placebo-controlled trials. Lancet Infect Dis. 2006; 6: 474–82.
63. Hickson M., D'Souza A. L., Muthu N. et al. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ. 2007; 335 (7610): 80.
64. Nista E. C., Candelli M., Cremonini F. et al. Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial. Aliment Pharmacol Ther. 2004; 20: 1181–8.
65. Beausoleil M., Fortier N., Guenette S. et al. Effect of a fermented milk combining Lactobacillus acidophilus C11285 and Lactobacillus casei in the prevention of antibiotic-associated diarrhea: a randomized, double-blind, placebo-controlled trial. Can J Gastroenterol. 2007; 21: 732–6.
66. Plummer S., Weaver M. A., Harris J. C. et al. Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of Clostridium difficile diarrhea. Int Microbiol. 2004; 7: 59–62.
67. Tong J. L., Ran Z. H., Shen J. et al. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther. 2007; 25: 155–68.
68. Sykora J., Valeckova K., Amlerova J. et al. Effects of a specially designed fermented milk product containing probiotic Lactobacillus casei DN-114 001 and the eradication Helicobacter pylori in children:prospective randomized double-blind study. J Clin Gastroenterol. 2005; 39: 692–8.
69. O'Mahony L., McCarthy J., Kelly P. et al. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005; 128: 541–51.
70. Gawronska A., Dziechciarz P., Horvath A., Szajewska H. A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children. Aliment Pharmacol Ther. 2007; 25: 177–84.
Рецензия
Для цитирования:
Урсова Н.И. ТЕРАПЕВТИЧЕСКИЙ ПОТЕНЦИАЛ СОВРЕМЕННЫХ ПРОБИОТИКОВ. Педиатрическая фармакология. 2013;10(2):46-56. https://doi.org/10.15690/pf.v10i2.644
For citation:
Ursova N.I. THERAPEUTIC POTENTIAL OF MODERN PROBIOTICS. Pediatric pharmacology. 2013;10(2):46-56. https://doi.org/10.15690/pf.v10i2.644
Просмотров:
833
Послать статью по эл. почте 